{"transactions":[{"id":772918,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:50:40.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18250,"source":{"system":"sec-edgar","filing":"0000905148-26-002535","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002535/form4.xml","form_type":"4"}},{"id":941897,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-09T21:30:18.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":92900,"source":{"system":"sec-edgar","filing":"0001104659-26-002491","document":"tm262627-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465926002491/tm262627-1_4seq1.xml","form_type":"4"}},{"id":1127319,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:42:07.000Z","date":"2025-05-30","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.69,"value":33800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at a price of $1.69. The reporting person undertakes to provide SELLAS Life Sciences Group, Inc., any security holder of SELLAS Life Sciences Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at the price set forth in this footnote."}],"balance_after":30400,"source":{"system":"sec-edgar","filing":"0001104659-25-055495","document":"tm2516957-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465925055495/tm2516957-1_4seq1.xml","form_type":"4"}},{"id":1132353,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:41.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001936","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001936/form4.xml","form_type":"4"}},{"id":1132352,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:41.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000905148-25-001936","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001936/form4.xml","form_type":"4"}},{"id":1303232,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T22:33:29.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":18500,"derivative":{"exercise_price":0.9525,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-25-003498","document":"tm253166-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465925003498/tm253166-5_4seq1.xml","form_type":"4"}},{"id":1303231,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T22:33:29.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":22900,"source":{"system":"sec-edgar","filing":"0001104659-25-003498","document":"tm253166-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465925003498/tm253166-5_4seq1.xml","form_type":"4"}},{"id":1499448,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T23:21:27.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":0.9075,"expiration_date":"2034-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905148-24-001656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001656/form4.xml","form_type":"4"}},{"id":1499447,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-29T23:21:27.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000905148-24-001656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001656/form4.xml","form_type":"4"}},{"id":1670721,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T11:02:26.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":10000,"derivative":{"exercise_price":0.5195,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-006397","document":"tm243935-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465924006397/tm243935-8_4seq1.xml","form_type":"4"}},{"id":1670720,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-25T11:02:26.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":10400,"source":{"system":"sec-edgar","filing":"0001104659-24-006397","document":"tm243935-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465924006397/tm243935-8_4seq1.xml","form_type":"4"}},{"id":1831090,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T22:45:36.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-23-034288","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034288/form4.xml","form_type":"4"}},{"id":1831089,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-12T22:45:36.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001140361-23-034288","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034288/form4.xml","form_type":"4"}},{"id":2032410,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:13:03.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":9500,"derivative":{"exercise_price":3.34,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001104659-23-010629","document":"tm235353d4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465923010629/tm235353d4_4seq1.xml","form_type":"4"}},{"id":2032409,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T22:13:03.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":4400,"source":{"system":"sec-edgar","filing":"0001104659-23-010629","document":"tm235353d4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465923010629/tm235353d4_4seq1.xml","form_type":"4"}},{"id":2056341,"issuer":{"id":95922,"kind":"organization","name":"ATHERSYS, INC / NEW","symbol":"ATHX"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-11T17:30:40.000Z","date":"2023-01-09","kind":"grant","acquired":true,"shares":22321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":35141,"source":{"system":"sec-edgar","filing":"0001368148-23-000017","document":"wf-form4_167345822333784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000136814823000017/wf-form4_167345822333784.xml","form_type":"4"}},{"id":2153911,"issuer":{"id":95922,"kind":"organization","name":"ATHERSYS, INC / NEW","symbol":"ATHX"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to purchase)","published_at":"2022-09-20T17:39:33.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":32042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the exempt acquisition of stock options to purchase 32,042 shares of the Issuer's Common Stock at a per share exercise price of $1.95.  These stock options in general will vest on July 28, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":64084,"derivative":{"exercise_price":1.95,"expiration_date":"2032-09-16","underlying":"Common Stock","underlying_shares":32042},"source":{"system":"sec-edgar","filing":"0001368148-22-000131","document":"wf-form4_166369556053492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000136814822000131/wf-form4_166369556053492.xml","form_type":"4"}},{"id":2153910,"issuer":{"id":95922,"kind":"organization","name":"ATHERSYS, INC / NEW","symbol":"ATHX"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T17:39:33.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":12820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the exempt acquisition of 12,820 restricted stock units that in general will vest in total on December 31, 2022, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-25 reverse stock split of its Common Stock (the \"Reverse Stock Split\")."}],"balance_after":12820,"source":{"system":"sec-edgar","filing":"0001368148-22-000131","document":"wf-form4_166369556053492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000136814822000131/wf-form4_166369556053492.xml","form_type":"4"}},{"id":2260453,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T21:50:31.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-05-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-22-020307","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020307/form4.xml","form_type":"4"}},{"id":2260452,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-23T21:50:31.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001140361-22-020307","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020307/form4.xml","form_type":"4"}},{"id":2418925,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T22:07:08.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":7125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":7125,"derivative":{"exercise_price":5.34,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":7125},"source":{"system":"sec-edgar","filing":"0001104659-22-010400","document":"tm225088-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465922010400/tm225088-6_4seq1.xml","form_type":"4"}},{"id":2418924,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-01T22:07:08.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0001104659-22-010400","document":"tm225088-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465922010400/tm225088-6_4seq1.xml","form_type":"4"}},{"id":2667856,"issuer":{"id":95922,"kind":"organization","name":"ATHERSYS, INC / NEW","symbol":"ATHX"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"NonQualified Stock Option (right to purchase)","published_at":"2021-06-15T21:39:15.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period."}],"balance_after":50000,"derivative":{"exercise_price":1.54,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001368148-21-000066","document":"wf-form4_162379312322561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000136814821000066/wf-form4_162379312322561.xml","form_type":"4"}},{"id":2701348,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T01:03:42.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":3.64,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-005769","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005769/edgar.xml","form_type":"4"}},{"id":2701347,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-22T01:03:42.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001179110-21-005769","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911021005769/edgar.xml","form_type":"4"}},{"id":2802717,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-08T21:29:16.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":7500,"derivative":{"exercise_price":8,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-033298","document":"tm218923d5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465921033298/tm218923d5_4.xml","form_type":"4"}},{"id":2979484,"issuer":{"id":95922,"kind":"organization","name":"ATHERSYS, INC / NEW","symbol":"ATHX"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"NonQualified Stock Option (right to purchase)","published_at":"2020-11-16T20:44:29.000Z","date":"2020-11-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award of a nonqualified stock option. The option vests one-third on the one-year anniversary date from the date of grant, and the remainder vests on a quarterly basis over years two and three."}],"balance_after":100000,"derivative":{"exercise_price":1.88,"expiration_date":"2030-11-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001368148-20-000133","document":"wf-form4_160555945689038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000136814820000133/wf-form4_160555945689038.xml","form_type":"4"}},{"id":3147593,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-16T00:56:13.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.765,"expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001179110-20-006135","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/edgar.xml","form_type":"4"}},{"id":3208352,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-17T01:20:16.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":6500,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001104659-20-034290","document":"tm2012902-6_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000110465920034290/tm2012902-6_form4.xml","form_type":"4"}},{"id":3353161,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2019-12-04T07:53:34.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":2227,"price":1.5953,"value":3552.7331,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":117420,"source":{"system":"sec-edgar","filing":"0001209191-19-058939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119058939/doc4.xml","form_type":"4"}},{"id":3375234,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-12T08:17:55.000Z","date":"2019-11-07","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the issuer's 2015 Omnibus Incentive Compensation Plan.  The shares subject to the options vest in equal quarterly installments over two years beginning on November 7, 2019 with the first quarterly installment vesting on February 7, 2020."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-19-055909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119055909/doc4.xml","form_type":"4"}},{"id":3512126,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-24T21:18:48.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest monthly over one (1) year) from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors."}],"balance_after":13750,"derivative":{"exercise_price":2.02,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001179110-19-006700","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/edgar.xml","form_type":"4"}},{"id":3565854,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option ( Right to Buy)","published_at":"2019-04-03T22:36:42.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services."}],"balance_after":80000,"derivative":{"exercise_price":2.42,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001179110-19-004740","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/edgar.xml","form_type":"4"}},{"id":3590132,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-18T23:03:54.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":25000,"derivative":{"exercise_price":1.38,"expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-008206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000089924319008206/doc4.xml","form_type":"4"}},{"id":3600154,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-12T16:25:34.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":21355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019."}],"balance_after":21355,"derivative":{"exercise_price":13.51,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":21355},"source":{"system":"sec-edgar","filing":"0001209191-19-018799","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018799/doc4.xml","form_type":"4"}},{"id":3600153,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2019-03-12T16:25:34.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":12813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022."}],"balance_after":119647,"source":{"system":"sec-edgar","filing":"0001209191-19-018799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018799/doc4.xml","form_type":"4"}},{"id":3636719,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2019-02-25T16:21:17.000Z","date":"2019-02-21","kind":"tax_withholding","acquired":false,"shares":953,"price":13.38,"value":12751.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":106834,"source":{"system":"sec-edgar","filing":"0001209191-19-012980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119012980/doc4.xml","form_type":"4"}},{"id":3718339,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-12-27T08:16:36.000Z","date":"2018-12-22","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":107787,"source":{"system":"sec-edgar","filing":"0001209191-18-064144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118064144/doc4.xml","form_type":"4"}},{"id":3742191,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-12-06T08:42:18.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":3067,"price":20.5241,"value":62947.4147,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from equity vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0500 to $20.7900 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":105287,"source":{"system":"sec-edgar","filing":"0001209191-18-061119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118061119/doc4.xml","form_type":"4"}},{"id":3771808,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-11-07T16:13:39.000Z","date":"2018-11-05","kind":"tax_withholding","acquired":false,"shares":955,"price":20.28,"value":19367.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":108354,"source":{"system":"sec-edgar","filing":"0001209191-18-057560","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118057560/doc4.xml","form_type":"4"}},{"id":3818774,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-09-12T16:21:20.000Z","date":"2018-09-10","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":109309,"source":{"system":"sec-edgar","filing":"0001209191-18-050640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118050640/doc4.xml","form_type":"4"}},{"id":3895132,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-13T22:31:11.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":5500,"derivative":{"exercise_price":5.23,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-18-037551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000120919118037551/doc4.xml","form_type":"4"}},{"id":3994337,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-16T00:03:34.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":11000,"derivative":{"exercise_price":5.24,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-18-020021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352455/000120919118020021/doc4.xml","form_type":"4"}},{"id":4001626,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-03-12T08:40:46.000Z","date":"2018-03-08","kind":"tax_withholding","acquired":false,"shares":2470,"price":25.65,"value":63355.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":106809,"source":{"system":"sec-edgar","filing":"0001209191-18-018703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118018703/doc4.xml","form_type":"4"}},{"id":4008989,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-03-07T07:54:50.000Z","date":"2018-03-05","kind":"exercise","acquired":false,"shares":2980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to these options vested in installments and were fully vested on 01/01/2012."}],"balance_after":0,"derivative":{"exercise_price":19.81,"expiration_date":"2018-03-05","underlying":"Common Stock","underlying_shares":2980},"source":{"system":"sec-edgar","filing":"0001209191-18-017582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118017582/doc4.xml","form_type":"4"}},{"id":4008988,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-03-07T07:54:50.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":2274,"price":25.95,"value":59010.3,"ownership":{"direct":true},"balance_after":109279,"source":{"system":"sec-edgar","filing":"0001209191-18-017582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118017582/doc4.xml","form_type":"4"}},{"id":4008987,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-03-07T07:54:50.000Z","date":"2018-03-05","kind":"exercise","acquired":true,"shares":2980,"price":19.81,"value":59033.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."}],"balance_after":111553,"source":{"system":"sec-edgar","filing":"0001209191-18-017582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118017582/doc4.xml","form_type":"4"}},{"id":4034879,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-02-26T08:42:11.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":6463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":108573,"source":{"system":"sec-edgar","filing":"0001209191-18-013213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118013213/doc4.xml","form_type":"4"}},{"id":4092589,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-23T07:52:43.000Z","date":"2018-01-19","kind":"exercise","acquired":false,"shares":34520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to these options vested in installments and were fully vested on 1/01/2012."}],"balance_after":2980,"derivative":{"exercise_price":19.81,"expiration_date":"2018-03-05","underlying":"Common Stock","underlying_shares":34520},"source":{"system":"sec-edgar","filing":"0001209191-18-004824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118004824/doc4.xml","form_type":"4"}},{"id":4092588,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-01-23T07:52:43.000Z","date":"2018-01-19","kind":"sale","acquired":false,"shares":350,"price":28.6286,"value":10020.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $28.60 to $28.80 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":102110,"source":{"system":"sec-edgar","filing":"0001209191-18-004824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118004824/doc4.xml","form_type":"4"}},{"id":4092587,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-01-23T07:52:43.000Z","date":"2018-01-19","kind":"sale","acquired":false,"shares":34170,"price":27.5768,"value":942299.256,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.10 to $28.00 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":102460,"source":{"system":"sec-edgar","filing":"0001209191-18-004824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118004824/doc4.xml","form_type":"4"}},{"id":4092586,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2018-01-23T07:52:43.000Z","date":"2018-01-19","kind":"exercise","acquired":true,"shares":34520,"price":19.81,"value":683841.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."}],"balance_after":136630,"source":{"system":"sec-edgar","filing":"0001209191-18-004824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118004824/doc4.xml","form_type":"4"}},{"id":4143023,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2017-12-05T07:46:41.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":4564,"price":20.522,"value":93662.408,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from equity vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.10 to $20.90 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":102110,"source":{"system":"sec-edgar","filing":"0001209191-17-063699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117063699/doc4.xml","form_type":"4"}},{"id":4405883,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-03T16:38:13.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017."}],"balance_after":12500,"derivative":{"exercise_price":27.475,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-17-017623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017623/doc4.xml","form_type":"4"}},{"id":4405882,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2017-03-03T16:38:13.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020."}],"balance_after":106674,"source":{"system":"sec-edgar","filing":"0001209191-17-017623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017623/doc4.xml","form_type":"4"}},{"id":4454780,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-13T16:16:40.000Z","date":"2017-02-09","kind":"exercise","acquired":false,"shares":54536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to these options vested in installments and were fully vested on 10/01/2010."}],"balance_after":0,"derivative":{"exercise_price":22.13,"expiration_date":"2017-02-14","underlying":"Common Stock","underlying_shares":54536},"source":{"system":"sec-edgar","filing":"0001209191-17-009976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117009976/doc4.xml","form_type":"4"}},{"id":4454779,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2017-02-13T16:16:40.000Z","date":"2017-02-09","kind":"sale","acquired":false,"shares":54536,"price":22.3012,"value":1216218.2432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $22.25 to $22.95 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":101674,"source":{"system":"sec-edgar","filing":"0001209191-17-009976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117009976/doc4.xml","form_type":"4"}},{"id":4454778,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2017-02-13T16:16:40.000Z","date":"2017-02-09","kind":"exercise","acquired":true,"shares":54536,"price":22.13,"value":1206881.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised."}],"balance_after":156210,"source":{"system":"sec-edgar","filing":"0001209191-17-009976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117009976/doc4.xml","form_type":"4"}},{"id":4533949,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2016-12-05T17:15:39.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":100,"price":21.3,"value":2130.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."}],"balance_after":101674,"source":{"system":"sec-edgar","filing":"0001209191-16-153415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116153415/doc4.xml","form_type":"4"}},{"id":4533948,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2016-12-05T17:15:39.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":3247,"price":20.7176,"value":67270.0472,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.20 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":101774,"source":{"system":"sec-edgar","filing":"0001209191-16-153415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116153415/doc4.xml","form_type":"4"}},{"id":4585060,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2016-10-05T16:18:00.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":3750,"price":20.7805,"value":77926.875,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.6700 to $20.9121 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":105021,"source":{"system":"sec-edgar","filing":"0001209191-16-144914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116144914/doc4.xml","form_type":"4"}},{"id":4594551,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-09-27T08:01:08.000Z","date":"2016-09-23","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to these options vested in installments and were fully vested on September 25, 2010."}],"balance_after":0,"derivative":{"exercise_price":8.5,"expiration_date":"2016-09-25","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-16-142858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116142858/doc4.xml","form_type":"4"}},{"id":4594550,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2016-09-27T08:01:08.000Z","date":"2016-09-23","kind":"sale","acquired":false,"shares":500,"price":27.3206,"value":13660.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised."}],"balance_after":108771,"source":{"system":"sec-edgar","filing":"0001209191-16-142858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116142858/doc4.xml","form_type":"4"}},{"id":4594549,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":46095,"kind":"person","name":"Wasman Jane","position":1,"cik":"0001352455","reported_name":"Wasman Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Intl and GC"}}],"security":"Common Stock","published_at":"2016-09-27T08:01:08.000Z","date":"2016-09-23","kind":"exercise","acquired":true,"shares":500,"price":8.5,"value":4250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised."}],"balance_after":109271,"source":{"system":"sec-edgar","filing":"0001209191-16-142858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116142858/doc4.xml","form_type":"4"}}]}